Introducing outpatient parenteral antimicrobial therapy in a children’s hospital
Sally Bolsover Outpatient parenteral antimicrobial therapy clinical nurse specialist/lead nurse, Sheffield Children’s NHS Foundation Trust, Sheffield, England
Outpatient parenteral antimicrobial therapy (OPAT) offers an alternative to inpatient care for delivering intravenous antibiotics in patients’ homes or in a day care clinic setting. It was first introduced in North America in the 1970s and has evolved over the years, starting with the adult population and now moving to the paediatric population (Chapman 2013). OPAT has the potential to offer excellent, patient-centred, high-quality care to treat a wide variety of infectious conditions in patients who are medically stable and do not need hospitalisation. For children and young people OPAT has the potential for families to resume their normal lives: returning to work, school and home. Paediatric OPAT (P-OPAT) is being implemented across the UK, with five centres now established. This article reports on the implementation of P-OPAT at Sheffield Children’s NHS Foundation Trust (Sheffield Children’s) in June 2016, highlighting the challenges and successes.
Nursing Children and Young People.
30, 01, 24-27.
This article has been subject to open peer review and has been checked for plagiarism using automated software
Conflict of interest
Write for us
For information about writing for RCNi journals, contact firstname.lastname@example.org
For author guidelines, go to rcni.com/writeforus
Received: 04 July 2017
Accepted: 07 November 2017
Want to read more?
Already subscribed? Log in
Unlock full access to RCNi Plus today
Save over 50% on your first 3 months
Your subscription package includes:
- Unlimited online access to all 10 RCNi Journals and their archives
- Customisable dashboard featuring 200+ topics
- RCNi Learning featuring 180+ RCN accredited learning modules
- RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests
Alternatively, you can purchase access to this article for the next seven days. Buy now